Forecast and Trends Prescription Hormonal Drugs in Gynecology - Global Industry Analysis, Size, Share, Growth 2016 - 2024
"Prescription
Hormonal Drugs in Gynecology Market - Global Industry Analysis, Size,
Share, Growth, Trends and Forecast 2016 - 2024"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
.
.
Description-
'
'
--
Global
Prescription Hormonal Drugs Market in Gynecology: Description
Hormonal imbalance in women is caused due to
abnormalities in the secretion of estrogen, progesterone and as well
as androgens. A wide array of symptoms might be experienced by
patients depending on the type of abnormality such as hot flushes,
depression, vaginal dryness, excessive hair growth and abnormal
vaginal bleeding. Environmental and genetic factors have an influence
on women's fertility through their effect on hormonal function.
Similarly, dysfunction of the HPO (hypothalamic-pituitary-ovarian)
axis and/or other endocrine systems may cause infertility and other
gynecological disorders. The correct clinical decision for treating
these diseases can be made on pathogenetic basis.
Get
Sample
Report
With TOC @
https://www.researchmoz.us/enquiry.php?type=S&repid=1357474
'
'
--
Global
Prescription Hormonal Drugs Market in Gynecology: Disease Overview
Disturbances related to the menstrual cycle lead
to various syndromes such as polycystic ovary syndrome (PCOS),
amenorrhea and premenstrual syndrome (PMS). Of all the above, PCOS is
a common hormonal disorder seen among women that in the reproductive
age. PCOS is a condition in which appearance of the ovaries in most,
but not all women, is enlarged and features a number of tiny cysts
located along the outer edge of each ovary. PCOS symptoms are
observed in nearly 5% to 10% of women who are in their reproductive
age (typically between 12 to 45 years).
PCOS is perceived to be among the leading causes
of female sub-fertility. It is also among the most frequently
reported endocrine problems in women in the reproductive age.
Amenorrhea is a clinical condition wherein menstrual periods do not
occur. Besides phases such as childhood, breastfeeding, pregnancy,
and menopause, the absence of periods may point toward a problem in
the female reproductive system. However, hormonal disruption is also
a common cause for the absence of menstrual periods. Similarly, PMS
is a medical condition that affects many women with childbearing age
and causes variety of physical and psychological symptoms that occur
just before menstrual cycle.
The prevalence of hormonal imbalance rate in women
is high as the World Health Organization (WHO) estimates that PCOS
affected 116 million women worldwide as of 2010 i.e. nearly 3.4%
of the global female population. While in case of PMS, according to
World Health Organization (WHO), in 2010, 199 million women had
premenstrual syndrome i.e. nearly 5.8% of the global female
population.
--
Global Prescription
Hormonal Drugs Market in Gynecology: Drivers and Restraints
The major drivers of the hormonal drugs in
gynecology market includes high awareness in female population
regarding hormonal disorders, continuous research and development
activities in the field of women healthcare and various government
and organizational programs to educate women about the symptoms,
precautions and treatments. The market for hormonal drugs in
gynecology can be segmented on the basis of different drugs available
in the market, different disease conditions and geography. Various
drugs available for the treatment of hormonal disorders includes
Depo-Provera, Prometrium, Provera, Alesse, Apri, Desogen, Junel Fe
1/20, Kariva, Loestrin Fe1/20, Vestura and others. Geographic segment
of prescription hormonal drugs in gynecology market can be
categorized into following regions: North America, Europe,
Asia-Pacific and Rest of the World.
Brisdelle (low-dose paroxetine mesylate) product
of Noven Pharmaceutical received approval in July 2013 against
treatment of menopause condition. Brisdelle is a low-dose formulation
of paroxetine mesylate, a selective serotonin reuptake inhibitor.
Similarly, the new entity AZD4901 (Oral) is currently under phase II
clinical trial for treatment of PCOS and this study is sponsored by
Astra Zeneca. It is an interventional type of study including 56 as
the target sample size.
The major players of prescription hormonal drugs
in gynecology market includes Novartis AG, Pfizer, Inc., Berlex
Laboratories, Inc., Ferring Pharmaceuticals, S.A., Duramed
Pharmaceuticals, Inc. Xanodyne Pharmaceuticals, Inc., Bayer AG and
others.
The report offers a comprehensive evaluation of
the market. It does so via in-depth qualitative insights, historical
data, and verifiable projections about market size. The projections
featured in the report have been derived using proven research
methodologies and assumptions. By doing so, the research report
serves as a repository of analysis and information for every facet of
the market, including but not limited to: Regional markets,
technology, types, and applications.
--
The study is a source
of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
--
The regional analysis
covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Poland, Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia and New Zealand)
- Middle East and Africa (GCC, Southern Africa, North Africa)
The report has been compiled through extensive
primary research (through interviews, surveys, and observations of
seasoned analysts) and secondary research (which entails reputable
paid sources, trade journals, and industry body databases). The
report also features a complete qualitative and quantitative
assessment by analyzing data gathered from industry analysts and
market participants across key points in the industry’s value
chain.
A separate analysis of prevailing trends in the
parent market, macro- and micro-economic indicators, and regulations
and mandates is included under the purview of the study. By doing so,
the report projects the attractiveness of each major segment over the
forecast period.
--
Highlights of the
report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
--
Note: Although
care has been taken to maintain the highest levels of accuracy in
TMR’s reports, recent market/vendor-specific changes may take time
to reflect in the analysis.
.
.
Report
Enquiry and Other Query @
https://www.researchmoz.us/enquiry.php?type=E&repid=1357474
Comments
Post a Comment